MedTrace Logo

Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

NCT04913103 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2021-06-04

No results posted yet for this study

Summary

A Czech Lymphoma Study Group, phase II, open-label, study of polatuzumab-vedotin in combination with bendamustine and rituximab for patients with mantle cell lymphoma, who relapse after previous therapy with Bruton tyrosine kinase inhibitor

Conditions

  • Lymphoma, Mantle-Cell

Interventions

DRUG

Polatuzumab vedotin

treatment by a study drug polatuzumab-vedotin, i.v.

DRUG

Bendamustine Hydrochloride

treatment by a study drug bendamustin i.v.

DRUG

Rituximab

treatment by a study drug rituximab, i.v.

Sponsors & Collaborators

  • Czech Lymphoma Study Group

    lead OTHER

Principal Investigators

  • Pavel Klener, Prof.MD,PhD · Czech Lymphoma Study Group

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2026-08-31
Completion
2027-08-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04913103 on ClinicalTrials.gov